Skip to main content

Stopping MS drugs raised brain scan activity in stable MS

By MS Buddy ·

Summarized from JAMA neurology, Dec 2024 · PubMed · DOI. AI-generated summary. Not medical advice.

Randomized trial · 89 people with relapse-onset MS stable on first-line treatment

Research by Eline Coerver, Eva Strijbis and 26 colleagues at Amsterdam University Medical Center location VUmc, Vrije Universiteit Amsterdam and 8 other institutions in the Netherlands.

Does stopping first-line MS treatment after years of stable disease raise relapse risk?

Key Takeaway

People with stable MS who stopped first-line treatment had more new brain scan changes than those who continued.

Blue-gray brain outline with fine nerve fibers and a few small shaded areas on a neutral background.
Credibility
Interest
Share:1 min read

What They Found

The trial compared stopping first-line MS treatment with continuing it. Eight of 45 people who stopped had new disease activity, compared with none of 44 who continued. Most new activity appeared on brain scans rather than as a flare-up. Two people who stopped treatment had a flare-up. Researchers ended the trial early because new disease activity exceeded a limit they had set.

Who Should Care and Why

The study included adults with MS that began with flare-ups. They had taken first-line treatment without a flare-up or major new brain scan changes for at least 5 years. The findings concern people considering whether to stop treatment after years of stable MS. Participants received care at 14 centers in the Netherlands. Their results show that stable MS can become active again after treatment stops.

Important Considerations

If you have stable MS, this trial does not show what would happen to you after stopping treatment. It included 89 people and ended early, after about 15 months of follow-up for the typical participant. The abstract does not report long-term disability outcomes.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in JAMA neurology by et al.. Reproduced from the PubMed record.

Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy. To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS. This multicenter, rater-blinded, noninferiority randomized clinical trial was conducted between July 1, 2020, and March 20, 2023, at 14 Dutch centers. Data analysis was performed between July 2023 and January 2024. Key inclusion criteria were relapse-onset MS, aged 18 years or older, without relapses, and without substantial magnetic resonance imaging (MRI) activity in the previous 5 years under first-line DMT. Participants were randomized 1:1 to discontinue or continue first-line DMT. Discontinuation of first-line DMT. The primary outcome was significant inflammatory disease activity, defined as relapse and/or 3 or more new T2 lesions or 2 or more contrast-enhancing lesions on brain MRI. Of 163 potentially eligible participants, 89 participants were included in the trial at the moment of early termination. Forty-four participants (49.4%) were assigned to the continue group and 45 participants (50.6%) were assigned to the discontinue group. Median (IQR) age was 54.0 (49.0-59.0) years, and 60 participants (67.4%) were female. Two participants in the continue group were lost to follow-up. After a median (IQR) follow-up time of 15.3 (11.4-23.9) months, the trial was prematurely terminated because of inflammatory disease activity recurrence above the predefined limit. In total, 8 of 45 participants in the discontinue group (17.8%) vs 0 of 44 participants in the continue group reached the primary end point and had recurrent, mostly radiological inflammation. Two of these 8 participants had a clinical relapse. Median (IQR) time to disease activity was 12.0 (6.0-12.0) months. In this randomized clinical trial, even in patients with long-term MS stable for over 5 years, first-line DMT discontinuation can lead to recurrence of inflammatory disease activity. Although this study cohort was relatively small, the recurrence of inflammation in the discontinue group was significantly higher than in the continue group and also higher than in the previously published DISCOMS trial, which only included individuals aged 55 years or older. This study provides additional data, especially in a younger population and including longitudinal biomarker measurements, for informed decision-making in cases when treatment discontinuation is considered. ClinicalTrials.gov Identifier: NCT04260711.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
Muted blue paths widen and join across soft gray layers on an off-white background.
MS treatment in Poland started sooner, reached more people

11/13/2026

From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru

Read More
Cut-paper laptop with a blank screen beside two equal curved paths on a warm background.
Online mindfulness course to test depression in MS care

1/1/2026

A planned study will test whether an online mindfulness course reduces depression in people with MS.

Read More
Two parallel paths cross uneven ground; one has fewer steep rises than the other.
Ocrevus cut disability worsening in high-risk relapsing MS

1/1/2027

In treatment trials, Ocrevus lowered disability worsening risk for a high-risk group with relapsing

Read More
Can MRI Scans Help Tell a True MS Relapse From a Flare?

11/3/2026

A study of two MS medicines found MRI scans may help confirm relapses and clarify treatment differen

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.